Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Clinical Trial Report Overview
A total of 97 Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) clinical trials were conducted as of March 2024. The Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) clinical trial report provides a comprehensive understanding of the Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials.
Key Regions | · North America
· Europe · Asia-Pacific · Middle East and Africa · South and Central America |
Key Countries | · The US
· The UK · Brazil · Germany · Italy |
Key Sponsor Types | · Company
· Institution · Government |
Leading Sponsors | · Sanofi
· JCR Pharmaceuticals Co Ltd · BioMarin/Genzyme LLC · BioMarin Pharmaceutical Inc · Sangamo Therapeutics Inc |
Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Clinical Trials Segmentation by Regions and Countries
As of March 2024, North America accounted for the highest number of Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) clinical trials with more than 50% of the clinical trials conducted there
The key regions considered for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) clinical trials analysis are North America, Europe, Asia-Pacific, the Middle East and Africa, and South and Central America.
In the country-wise analysis, the US had the highest number of Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) clinical trials as of March 2024. Australia had the highest average patient enrollment in Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) clinical trials during the same time.
G7 countries: Among the G7 (United States, United Kingdom, Germany, France, Italy, Canada, and Japan) countries, the US had the highest proportion of Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) to metabolic disorders clinical trials as of March 2024.
E7 countries: Among the E7 (Brazil, Russia, India, China, Mexico, Turkey, and Indonesia) countries, Brazil had the highest proportion of Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) to metabolic clinical trials as of March 2024.
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Clinical Trials Analysis by Regions, 2024 (%)
Buy the Full Report for More Regional Insights into the Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Clinical Trials
Download a Free Sample Report
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Clinical Trials Segmentation by Sponsor Types
The key sponsor types for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) clinical trials are company, institution, and the government. As of March 2024, more than 50% of the Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) clinical trials were sponsored by company sponsor type, followed by institution.
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Clinical Trials Analysis by Sponsor Types, 2024 (%)
Buy the Full Report for More Sponsor Type Insights into the Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Clinical Trials
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Clinical Trials - Competitive Landscape
In 2024, Sanofi conducted the highest number of Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) clinical trials
A few of the leading sponsors for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) clinical trials are:
- Sanofi
- JCR Pharmaceuticals Co Ltd
- BioMarin/Genzyme LLC
- BioMarin Pharmaceutical Inc
- Sangamo Therapeutics Inc
- Altasciences Co Inc
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Clinical Trials Analysis by Sponsors, 2024 (%)
Buy the Full Report to Know More about the Leading Sponsors of Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Clinical Trials
Segments Covered in the Report
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Clinical Trials Regional Outlook (2024)
- North America
- Europe
- Asia-Pacific
- Middle East and Africa
- South and Central America
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Clinical Trials Country Outlook (2024)
- The US
- The UK
- Brazil
- Germany
- Italy
- Netherlands
- Canada
- Japan
- Russia
- Australia
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Clinical Trials Sponsor Type Outlook (2024)
- Company
- Institution
- Government
Scope
- The report provides a snapshot of the global clinical trials landscape.
- The report provides top-level data related to the clinical trials by region, country (G7 & E7), trial status, trial phase, sponsor type, and endpoint status.
- The report reviews the top companies involved and enlists all trials (trial title, phase, and status) of the company.
- The report provides all the unaccomplished trials (terminated, suspended, and withdrawn) with a reason for accomplishment.
- The report provides enrollment trends for the past five years.
- The report provides the latest news for the past three months.
Reasons to Buy
- Formulate key business strategies about investment.
- Identify prominent locations for conducting clinical trials which saves time and cost.
- Get top-level analysis of the Global Clinical Trials Market which helps in identifying key business opportunities.
- Understand trial count and enrollment trends by country in the global therapeutics market.
- Interpret the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended, or withdrawn) trials.
- Understand clinical trial assessment of the indication on a global, regional, and country level.
JCR Pharmaceuticals Co Ltd
BioMarin/Genzyme LLC
BioMarin Pharmaceutical Inc
Sangamo Therapeutics Inc
Altasciences Co Inc
Dianthus Therapeutics Inc
Medpace Holdings Inc
RegenxBio Inc
Jupiter Neurosciences Inc
Table of Contents
Table
Figures
Frequently asked questions
-
Which region accounted for the highest number of Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) clinical trials in March 2024?
North America accounted for the highest number of Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) clinical trials as of March 2024.
-
Which country conducted the highest number of Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) clinical trials in March 2024?
The US conducted the highest number of Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) clinical trials as of March 2024.
-
Which sponsor type was the most prominent in the Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) clinical trials in March 2024?
As of March 2024, most of the Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) clinical trials conducted were sponsored by company sponsor type.
-
Which are the leading sponsors of Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) clinical trials?
A few of the leading sponsors of Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) clinical trials are Sanofi, JCR Pharmaceuticals Co Ltd, BioMarin/Genzyme LLC, BioMarin Pharmaceutical Inc, Sangamo Therapeutics Inc, and Altasciences Co Inc, among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.